Starting fall 2026, children in the Netherlands will receive a new HPV vaccine that protects against nine strains of the human papillomavirus (HPV), replacing the current vaccine coverage of only two strains. The Dutch Ministry of Public Health, led by caretaker State Secretary Judith Tielen, announced this change following expert recommendations from the Health Council.
What Is HPV and Why Vaccinate?
HPV is a common virus transmitted through skin-to-skin contact, including during sexual activity. While many HPV infections resolve on their own, certain strains can cause serious health problems including cervical cancer, as well as other cancers affecting men and women.
In the Netherlands, approximately 1,100 women and 400 men are diagnosed with HPV-related cancers each year. Vaccination has proven to be a highly effective preventive tool: women vaccinated against HPV have about 90% lower rates of cervical cancer compared to unvaccinated women. Additionally, severe precancerous cervical lesions are reduced by 80%.
The New 9-Valent HPV Vaccine
The updated vaccine expands coverage from two HPV types to nine (hence “9-valent”), offering protection against a broader range of high-risk HPV strains linked to cancers. According to the Health Council and supported by scientific studies, the new vaccine works as effectively as the previous one but offers more comprehensive cancer prevention.
Tielen explained, “This new vaccine achieves an even greater effect: it protects against nine types of HPV instead of two. This means a significantly lower risk of cervical cancer, other forms of cancer, and their precancerous lesions.”
Vaccination Program Details and Preparation
Currently, children in the Netherlands receive their first HPV vaccine dose during the year they turn 10, followed by a second dose later. The rollout of the 9-valent vaccine is planned for the fall of 2026, with preparation underway to ensure smooth implementation.
Tielen noted that about 75% of girls and 50% of boys invited to participate will receive the vaccine, involving thousands of vaccinations in total. “We need thorough preparations to manage this transition successfully,” she said.
Conclsion
Health experts in the Netherlands anticipate that switching to the 9-valent HPV vaccine will strengthen the country’s fight against HPV-related cancers by preventing infections from more high-risk virus types. Wider protection is expected to contribute to further declines in incidence rates of cervical and other HPV-linked cancers over time.
This update also aligns the Netherlands with vaccination programs in several other countries that have already adopted the broader vaccine, reflecting growing global consensus on improving HPV prevention.
Related topics
